AD Antibody — Passive Immunization Treatment for Alzheimer's Disease
A monoclonal antibody (mAbSL) that is highly selective for the particular form of amyloid-beta protein that is the primary trigger for Alzheimer's Disease onset, with promise as a passive immunization therapy.
Technology overview
The accumulation of aggregated amyloid-beta protein (Aβ) — senile plaques, oligomers, and protofibrils — is at the core of Alzheimer's Disease. Researchers at the University of Missouri–St. Louis have characterized the monoclonal antibody mAbSL, which is highly selective for a particular form of the protein that is the primary trigger for AD onset. The mAbSL antibody shows promise for a passive immunization treatment given at the early stage of AD and may stop or even reverse AD progression. Development stage: Researchers have obtained, cloned, sequenced, expressed, purified, and characterized the monoclonal antibody. Next steps include production scale-up, animal studies in AD transgenic mice, and humanization of the mAbSL antibody. Polyclonal antibodies are also available for research purposes.
Commercial applications
Diagnosis and treatment of Alzheimer's Disease.
Key advantages
Higher selectivity to the main trigger of AD than other drugs in development. A therapeutic based on this technology could prevent the onset of AD and potentially reverse the disease, treating AD itself rather than only the symptoms or slowing progression.
Licensing
Available as: Exclusive
Connect with the technology transfer office to discuss terms.
Inquire about licensing Email directly